UC Davis scientists are putting a high-tech twist on a familiar cancer dream: hit the tumor hard and leave everything else alone. Researchers say they are testing smart nanoparticles that travel to cancer sites, then transform into sticky nanofiber networks that cling to tumors so doctors can effectively park drugs where they are needed most while sparing healthy tissue. The experimental platform is now in preclinical testing at the university's Experimental Therapeutics Laboratory.
The effort, led by Distinguished Professor Kit S. Lam, recently landed a $3.1 million NIH R01 research project grant to push the work forward, according to UC Davis Health. In the university's announcement, Lam called the award a chance to speed up development of "a whole new way of treating cancer." The team describes the platform as a two-component, two-step strategy that first locks in on tumors, then triggers drug delivery on demand later.
How the two-step system works
A federal grant record lays out the technical game plan: build transformable nanoparticles that home in on tumor receptors such as EGFR or the α3β1 integrin, then use advanced imaging to watch how those particles behave in living systems and finally test safety and cancer-fighting power in preclinical models, according to GovTribe. The application describes a TNP/TCTS setup, short for transformable nanoparticle and two-component two-step platform.
In this design, the particles are engineered to morph into a nanofibrillar network once they reach the tumor microenvironment. That sticky web can remain at the tumor site for up to a week while similar material clears from organs such as the liver and lungs in about two days, the abstract notes. Those timing differences are what allow clinicians, at least in theory, to "park" therapeutic payloads inside the tumor while giving the rest of the body a better break from harsh drugs.
Proven lab technique
Lam's group is not starting from scratch. The lab has already published proof-of-concept work showing that transformable peptide nanoparticles could shut down HER2 signaling and shrink tumors in mouse models, providing in-vivo evidence that the approach can work, as reported in Nature Nanotechnology. That 2020 study, along with related patents, underpins the current strategy to move peptide-based nanomaterials toward real-world therapeutic use.
The new grant builds directly on that earlier science while shifting the focus toward a bioorthogonal, on-demand delivery step that relies on highly specific "click chemistry" reactions. In practice, that means the team wants the tumor-anchored framework to act like a biochemical docking station that can be loaded with treatments only after it has safely settled at the cancer site.
Where this fits locally
The work is housed at the UC Davis Comprehensive Cancer Center, the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people, according to Becker's Hospital Review. The center treats more than 100,000 patients annually and offers access to hundreds of clinical trials, giving the nanoparticle team a built-in route for moving promising findings from bench to potential early human studies.
If the platform proves safe and effective in further testing, local oncologists and patients could eventually benefit from cancer therapies that are more precisely concentrated at tumor sites and less punishing on the rest of the body.
What’s next
Next up, the researchers plan to sharpen the technology's aim at cancers such as non-small cell lung cancer, refine imaging tools to track how the nanoparticles move and change in living systems, and run detailed tests of toxicity and anti-tumor activity in preclinical models, according to UC Davis Health. The team also intends to use the click-chemistry step to attach different kinds of treatments to the tumor-anchored scaffold, from small-molecule drugs to immune-boosting proteins.
If those steps work out, the platform could support sequential or combination therapies that are timed to hit when the tumor microenvironment is most vulnerable. Scientists involved in the project are quick to note that success in animal models does not guarantee the same results in people and emphasize that this is still early-stage work focused heavily on imaging and safety.
For now, the roadmap runs through more preclinical imaging and safety studies before any human trials are considered. But if the sticky, shape-shifting nanoparticles behave as hoped, the approach could eventually reshape how oncologists try to balance aggressive treatment with quality of life.
